头颈部肿瘤IMRT再程放疗的体积、剂量与分割考量:多机构分析
该多机构回顾性队列研究纳入505例既往放疗区(≥40 Gy)复发或第二原发头颈鳞癌并接受IMRT再程放疗(≥40 Gy)的患者,评估选择性淋巴结照射、剂量和分割对生存、局部区域控制及毒性的影响。结果显示根治性再程放疗剂量≥66 Gy与LRF和OS改善相关,术后再程放疗剂量50-66 Gy已足够;超分割和选择性颈部照射未见明显获益,且可能增加毒性。
要点
- 根治性再程IMRT剂量≥66 Gy与LRF和OS改善相关
- 术后再程IMRT剂量50-66 Gy在肉眼病灶切除后已足够
- 超分割和选择性颈部照射未见获益,可能增加毒性
核心结论
- 根治性再程IMRT剂量≥66 Gy可能改善高体能状态患者的结局。
- 术后再程IMRT在肉眼病灶切除后剂量50-66 Gy已足够。
- 超分割和选择性颈部照射未见明显获益,且可能增加毒性。
研究设计与样本
- 多机构回顾性队列研究,纳入8家机构的505例患者。
- 纳入标准为既往放疗区(≥40 Gy)复发或第二原发头颈鳞癌并接受IMRT再程放疗(≥40 Gy)。
- 采用Kaplan-Meier法和Gray竞争风险法评估生存、局部区域控制及急慢性毒性。
主要发现
- 56.4%的患者未接受选择性颈部照射。
- 再程IMRT中位剂量为60 Gy(范围39.6-79.2 Gy)。
- 20.2%的患者采用超分割,77.4%的患者整合了全身治疗。
- 选择性淋巴结照射未降低局部区域失败风险或改善OS。
- 急性≥3级毒性发生率为22.1%,总体晚期≥3级毒性发生率为16.7%。
关键数值与推荐
- 根治性再程IMRT剂量≥66 Gy与LRF和OS改善相关。
- 术后再程IMRT剂量对LRF或OS无明显影响。
- 超分割与LRF或OS改善无关。
- 多因素logistic回归显示术后选择性颈部照射与急性毒性增加相关。
- 术后超分割患者晚期≥3级毒性发生率最高。
临床怎么用
- 根治性再程IMRT可考虑剂量≥66 Gy以改善高体能状态患者结局。
- 术后再程IMRT在肉眼病灶切除后可采用50-66 Gy剂量。
- 避免常规使用超分割和选择性颈部照射以减少毒性。
局限性
- 回顾性研究设计可能存在选择偏倚。
- 多机构数据存在治疗技术和患者选择异质性。
- 剂量与结局的关联可能受混杂因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Limited data exist to guide the treatment technique for reirradiation of recurrent or second primary squamous carcinoma of the head and neck. We performed a multi-institution retrospective cohort study to investigate the effect of the elective treatment volume, dose, and fractionation on outcomes and toxicity. METHODS AND MATERIALS: Patients with recurrent or second primary squamous carcinoma originating in a previously irradiated field (≥40 Gy) who had undergone reirradiation with intensity modulated radiation therapy (IMRT); (≥40 Gy re-IMRT) were included. The effect of elective nodal treatment, dose, and fractionation on overall survival (OS), locoregional control, and acute and late toxicity were assessed. The Kaplan-Meier and Gray's competing risks methods were used for actuarial endpoints. RESULTS: From 8 institutions, 505 patients were included in the present updated analysis. The elective neck was not treated in 56.4% of patients. The median dose of re-IMRT was 60 Gy (range 39.6-79.2). Hyperfractionation was used in 20.2%. Systemic therapy was integrated for 77.4% of patients. Elective nodal radiation therapy did not appear to decrease the risk of locoregional failure (LRF) or improve the OS rate. Doses of ≥66 Gy were associated with improvements in both LRF and OS in the definitive re-IMRT setting. However, dose did not obviously affect LRF or OS in the postoperative re-IMRT setting. Hyperfractionation was not associated with improved LRF or OS. The rate of acute grade ≥3 toxicity was 22.1% overall. On multivariable logistic regression, elective neck irradiation was associated with increased acute toxicity in the postoperative setting. The rate of overall late grade ≥3 toxicity was 16.7%, with patients treated postoperatively with hyperfractionation experiencing the highest rates. CONCLUSIONS: Doses of ≥66 Gy might be associated with improved outcomes in high-performance patients undergoing definitive re-IMRT. Postoperatively, doses of 50 to 66 Gy appear adequate after removal of gross disease. Hyperfractionation and elective neck irradiation were not associated with an obvious benefit and might increase toxicity.
引用
- Caudell JJ, Ward MC, Riaz N, et al. Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis. Int J Radiat Oncol Biol Phys. 2017. PMID: 29413274. doi:10.1016/j.ijrobp.2017.11.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。